SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Schock Helena)
 

Sökning: WFRF:(Schock Helena) > A Prospective Evalu...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006061naa a2200889 4500
001oai:DiVA.org:umu-126738
003SwePub
008161013s2016 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:134224931
009oai:lup.lub.lu.se:e91031e6-db61-4003-a924-49c959297fc3
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1267382 URI
0247 a https://doi.org/10.1158/1078-0432.CCR-16-03162 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1342249312 URI
0247 a https://lup.lub.lu.se/record/e91031e6-db61-4003-a924-49c959297fc32 URI
040 a (SwePub)umud (SwePub)kid (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Terry, Kathryn L.u Harvard University4 aut
2451 0a A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort
264 1b American Association for Cancer Research,c 2016
338 a print2 rdacarrier
520 a Purpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate earlydetection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study. Experimental Design: We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. Results: We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. Conclusions: CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Schock, Helenau German Cancer Research Centre4 aut
7001 a Fortner, Renée T.u German Cancer Research Centre4 aut
7001 a Hüsing, Anikau German Cancer Research Centre4 aut
7001 a Fichorova, Raina N.u Brigham and Women's Hospital / Harvard Medical School4 aut
7001 a Yamamoto, Hidemi S.u Brigham and Women's Hospital / Harvard Medical School4 aut
7001 a Vitonis, Allison F.u Brigham and Women's Hospital / Harvard Medical School4 aut
7001 a Johnson, Theronu German Cancer Research Centre4 aut
7001 a Overvad, Kimu Aarhus University4 aut
7001 a Tjønneland, Anneu Danish Cancer Society4 aut
7001 a Boutron-Ruault, Marie-Christine4 aut
7001 a Mesrine, Sylvie4 aut
7001 a Severi, Gianluca4 aut
7001 a Dossus, Laure4 aut
7001 a Rinaldi, Sabina4 aut
7001 a Boeing, Heiner4 aut
7001 a Benetou, Vassiliki4 aut
7001 a Lagiou, Pagona4 aut
7001 a Trichopoulou, Antonia4 aut
7001 a Krogh, Vittorio4 aut
7001 a Kuhn, Elisabetta4 aut
7001 a Panico, Salvatore4 aut
7001 a Bueno-de-Mesquita, H. Bas4 aut
7001 a Onland-Moret, N. Charlotte4 aut
7001 a Peeters, Petra H.4 aut
7001 a Gram, Inger Torhild4 aut
7001 a Weiderpass, Elisabeteu Karolinska Institutet4 aut
7001 a Duell, Eric J.4 aut
7001 a Sanchez, Maria-Jose4 aut
7001 a Ardanaz, Eva4 aut
7001 a Etxezarreta, Nerea4 aut
7001 a Navarro, Carmen4 aut
7001 a Idahl, Annikau Umeå universitet,Obstetrik och gynekologi4 aut0 (Swepub:umu)anid0002
7001 a Lundin, Evau Umeå universitet,Patologi4 aut0 (Swepub:umu)evlu0001
7001 a Jirström, Karinu Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji
7001 a Manjer, Jonasu Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups4 aut0 (Swepub:lu)smi-jma
7001 a Wareham, Nicholas J.4 aut
7001 a Khaw, Kay-Tee4 aut
7001 a Byrne, Karl Smith4 aut
7001 a Travis, Ruth C.4 aut
7001 a Gunter, Marc J.4 aut
7001 a Merritt, Melissa A.4 aut
7001 a Riboli, Elio4 aut
7001 a Cramer, Daniel W.4 aut
7001 a Kaaks, Rudolf4 aut
7102 a Harvard Universityb German Cancer Research Centre4 org
7730 t Clinical Cancer Researchd : American Association for Cancer Researchg 22:18, s. 4664-4675q 22:18<4664-4675x 1078-0432x 1557-3265
8564 u http://dx.doi.org/10.1158/1078-0432.CCR-16-0316y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-126738
8564 8u https://doi.org/10.1158/1078-0432.CCR-16-0316
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:134224931
8564 8u https://lup.lub.lu.se/record/e91031e6-db61-4003-a924-49c959297fc3

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy